Global Prefilled Syringe Packaging Market 2016-2020

2015-12-02
Price :
Published : Dec-2015
No. of Pages : 69

The research analyst predicts the global prefilled syringe packaging market to grow at a CAGR of around 12% by 2020. The prefilled syringes are gaining popularity over parenteral drug delivery routes because of their high affordability, accuracy, and safety. Also, the ability of such syringes to reduce drug wastage, increase the useful drug lifespan, and increase the vendor’s market footprint will result in the growth of the market.

The augmented use of disposable medical products is the key driver for the growth of this market. Recently, it has been observed that many healthcare facilities prefer using disposable products as it reduces the risk of cross-contamination. This rise in the use of disposable products will lead to the augmented demand for plastics as a packaging material due to its cost-effectiveness when compared to glass and metallic materials.

Segmentation by material type and analysis of the prefilled syringe packaging market

  • Glass
  • Plastic

Though the glass prefilled syringes segment dominates this market in terms of total market shares, the plastic prefilled syringes segment will experience rapid growth during the forecast period. Since these syringes are break resistant and have the ability to protect drugs from moisture, their augmented adoption by healthcare facilities will lead to market growth during the estimated period.

Application-based segmentation of the prefilled syringe packaging market

  • Vaccines
  • Antithrombotic drugs

The market research analysts estimate the vaccines packaging segment to account for more than 58% of the total market share by the end of 2020. The ability of prefilled vaccine syringes to meet the needs to healthcare facilities, such as reducing wastage, decreasing the time for drug administration, and reducing the risks of errors and contamination, will foster its adoption for vaccination purposes during the forecast period.

Competitive landscape and key vendors

The global prefilled syringe packaging market is fragmented owing to the presence of several multinational, regional, and local vendors. The smaller and local vendors compete with the multinational vendors in terms of cost, as it is difficult for them to compete with international vendors in terms of quality, features, and range of offerings.

The leading vendors in the market are -

  • Baxter
  • Becton Dickinson
  • Gerresheimer
  • Nipro
  • Schott

The other prominent vendors in the market include Bespak, Bosch Packaging, Catalent, Ciron Groups, Corden Pharma, Health Biotech, MedXL, Novalek Pharmaceuticals, Stevanato Group, Troikaa, Unilife Vetter Pharma, West Pharmaceutical Services, and Ypsomed Holding.

Key questions answered in the report include

  • What will the market size and the growth rate be in 2020
  • What are the key factors driving the global prefilled syringe packaging market
  • What are the key market trends impacting the growth of the global prefilled syringe packaging market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the vendors in the global prefilled syringe packaging market
  • Trending factors influencing the market shares of the North America, APAC, Europe, and ROW.
  • What are the key outcomes of the five forces analysis of the global prefilled syringe packaging market
Filed in: Pharmaceutical
Publisher : Technavio
More Reports
Title Price Buy Now

EpiCast Report: Alzheimer’s Disease – Epidemiology Forecast to 2026

EpiCast Report: Alzheimer's Disease - Epidemiology Forecast to 2026 Summary Alzheimer's disease (AD) is a subtype of dementia and is an irreversible, neurodegenerative brain disease of the elderly, characterized by the death of brain cells, which leads to a progressive decline in memory and cognitive abilities, such as thinking, language, and learning capacity (NIA, 2017). AD is the most common cause of dementia in people age 60 years and older, and accounts for approximately 75% of the total dementia cases worldwide. To forecast the total prevalent cases of AD in adults ages 60 years and older in the 7MM during the forecast period (2016-2026), our epidemiologists identified country-specific population-based studies that used the diagnostic criteria based on the Diagnostic and Sta......
$3995

EpiCast Report: Epilepsy – Epidemiology Forecast to 2026

EpiCast Report: Epilepsy - Epidemiology Forecast to 2026 Summary Epilepsy is a brain disorder characterized by recurrent and unpredictable seizures that are caused by sudden, disorderly, and excessive neuronal activity in the brain (WHO, 2017). It is one of the most common neurological conditions globally (WHO, 2017). Epilepsy can start at any age and can be a life-long condition. It is diagnosed after a patient has suffered a seizure and is referred to a specialist, where a description of the symptoms before the seizure and the seizure itself are used for a diagnosis (NHS, 2014). In the 7MM, the lifetime diagnosed prevalent cases of epilepsy will increase from almost 11 million cases in 2016 to just over 11.5 million cases in 2026, at an Annual Growth Rate (AGR) of almost 0.5% pe......
$3995

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Argentina

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Argentina Summary Pharmaceutical market increased from over US$3 Billion in 2009 to around US$6.5 Billion in 2016, at a Compound Annual Growth Rate (CAGR) of nearly 10%. It is expected to cross US$10 Billion in 2021 at a CAGR of about 10%. In 2009, the medical device market was valued at just over US$1 Billion. It grew at a CAGR of 4% between 2009 and 2016 and reached around US$1.3 Billion. It is expected to grow at a CAGR of about 5%, from around US$1.4 Billion in 2017 to over US$1.7 Billion in 2021. Argentina is the third-largest pharmaceutical market in Latin America after Brazil and Mexico. With a relatively low-cost base and high-quality professionals in the biotechnology sector, Argentina is home to over 130 ......
$1995

Partnerships, Licensing, Investments and M&A Deals and Trends for August 2017 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for August 2017 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for August 2017 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in August 2017. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report p......
$1000

EpiCast Report: Melanoma – Epidemiology Forecast to 2026

EpiCast Report: Melanoma - Epidemiology Forecast to 2026 Summary Melanoma is a malignant neoplasm of melanocytes, the pigment cells in the skin located on the epidermis, the most superficial layer of skin (WHO, 2014). Melanocytes are embryological derivatives of neural crest tissue, and as such, any region of the body that is a derivative of the neural crest and contains melanocytes-namely areas of skin, meninges, mucous membranes, esophagus, and eyes-can develop melanoma (Komarnicky-Kocher and Alite, 2013). In the 7MM, our epidemiologists forecast the diagnosed incident cases of melanoma to increase to over 200,000 cases by 2026, at an Annual Growth Rate (AGR) of almost 2.5%. The US will have the highest number of melanoma cases throughout the forecast period. The five-year diagn......
$3995

EpiCast Report: Crohn’s Disease – Epidemiology Forecast to 2026

EpiCast Report: Crohn's Disease - Epidemiology Forecast to 2026 Summary Crohn's disease (CD) is an inflammatory bowel disease (IBD) characterized by chronic inflammation of the gastrointestinal tract. While any part of the gastrointestinal tract can be affected, inflammation is most commonly found at the end of the small intestine (ileum), and the start of the large intestine (colon). The disease course of CD is characterized by periods of remission followed by periods of relapse, the length and severity of which differ from case to case (CDC, 2014; NHS, 2015). Inflammation in CD can result in severe scarring and narrowing of the parts of the bowel. Our epidemiologists forecast that the diagnosed incident cases of CD in the 7MM will increase from 70,985 in 2016 to 74,712 in 2026 a......
$3995

Hypereosinophilic Syndrome Global Clinical Trials Review, H2, 2017

Hypereosinophilic Syndrome Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hypereosinophilic Syndrome Global Clinical Trials Review, H2, 2017" provides an overview of Hypereosinophilic Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Hypereosinophilic Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary dat......
$2500

Hyperglycemia Global Clinical Trials Review, H2, 2017

Hyperglycemia Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hyperglycemia Global Clinical Trials Review, H2, 2017" provides an overview of Hyperglycemia clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperglycemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clin......
$2500

Hyperkalemia Global Clinical Trials Review, H2, 2017

Hyperkalemia Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hyperkalemia Global Clinical Trials Review, H2, 2017" provides an overview of Hyperkalemia clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperkalemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical......
$2500

Hyperalgesia Global Clinical Trials Review, H2, 2017

Hyperalgesia Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hyperalgesia Global Clinical Trials Review, H2, 2017" provides an overview of Hyperalgesia clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperalgesia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical......
$2500